CytoSorbents to sell 34 million units through its public offering

Brean to raise proceeds for product development, sales and marketing

By Devika Patel

Knoxville, Tenn., Feb. 14 - CytoSorbents Corp. will sell up to 34 million units in its public sale, according to a Form S-1/A filed Friday with the Securities and Exchange Commission. The deal will be conducted on a best-efforts and no-minimum basis and was announced on Dec. 23.

The units will consist of one common share and a half-share warrant, which will be exercisable until 2019.

Brean Capital, LLC is the agent.

Proceeds will be used for product development, sales and marketing, clinical studies and general working capital purposes.

Based in Monmouth Junction, N.J., CytoSorbents is a medical device company that has developed a new adsorbent platform technology for removal of toxins from blood and physiologic fluids.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.